These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 26781064)
1. A double-negative feedback loop between EZH2 and miR-26a regulates tumor cell growth in hepatocellular carcinoma. Zhuang C; Wang P; Huang D; Xu L; Wang X; Wang L; Hu L Int J Oncol; 2016 Mar; 48(3):1195-204. PubMed ID: 26781064 [TBL] [Abstract][Full Text] [Related]
2. MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2. Ma DN; Chai ZT; Zhu XD; Zhang N; Zhan DH; Ye BG; Wang CH; Qin CD; Zhao YM; Zhu WP; Cao MQ; Gao DM; Sun HC; Tang ZY J Hematol Oncol; 2016 Jan; 9():1. PubMed ID: 26733151 [TBL] [Abstract][Full Text] [Related]
3. miR-26a promoted by interferon-alpha inhibits hepatocellular carcinoma proliferation and migration by blocking EZH2. Wang G; Sun Y; He Y; Ji C; Hu B; Sun Y Genet Test Mol Biomarkers; 2015 Jan; 19(1):30-6. PubMed ID: 25494962 [TBL] [Abstract][Full Text] [Related]
4. Reciprocal negative feedback loop between EZH2 and miR-101-1 contributes to miR-101 deregulation in hepatocellular carcinoma. Huang D; Wang X; Zhuang C; Shi W; Liu M; Tu Q; Zhang D; Hu L Oncol Rep; 2016 Feb; 35(2):1083-90. PubMed ID: 26718325 [TBL] [Abstract][Full Text] [Related]
5. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739 [TBL] [Abstract][Full Text] [Related]
6. MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma. Xia H; Ooi LL; Hui KM PLoS One; 2012; 7(9):e44206. PubMed ID: 22962603 [TBL] [Abstract][Full Text] [Related]
7. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Au SL; Wong CC; Lee JM; Fan DN; Tsang FH; Ng IO; Wong CM Hepatology; 2012 Aug; 56(2):622-31. PubMed ID: 22370893 [TBL] [Abstract][Full Text] [Related]
8. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2. Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878 [TBL] [Abstract][Full Text] [Related]
9. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma. Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240 [TBL] [Abstract][Full Text] [Related]
10. MicroRNA-1297 regulates hepatocellular carcinoma cell proliferation and apoptosis by targeting EZH2. Liu F; He Y; Shu R; Wang S Int J Clin Exp Pathol; 2015; 8(5):4972-80. PubMed ID: 26191190 [TBL] [Abstract][Full Text] [Related]
11. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis. Chen S; Pu J; Bai J; Yin Y; Wu K; Wang J; Shuai X; Gao J; Tao K; Wang G; Li H J Exp Clin Cancer Res; 2018 Jan; 37(1):3. PubMed ID: 29316949 [TBL] [Abstract][Full Text] [Related]
12. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer. Ling Z; Wang X; Tao T; Zhang L; Guan H; You Z; Lu K; Zhang G; Chen S; Wu J; Qian J; Liu H; Xu B; Chen M J Exp Clin Cancer Res; 2017 Nov; 36(1):159. PubMed ID: 29141691 [TBL] [Abstract][Full Text] [Related]
13. Potential roles of EZH2, Bmi-1 and miR-203 in cell proliferation and invasion in hepatocellular carcinoma cell line Hep3B. Yang F; Lv LZ; Cai QC; Jiang Y World J Gastroenterol; 2015 Dec; 21(47):13268-76. PubMed ID: 26715809 [TBL] [Abstract][Full Text] [Related]
14. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2. Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524 [TBL] [Abstract][Full Text] [Related]
15. LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7. Gao J; Dai C; Yu X; Yin XB; Zhou F Cell Cycle; 2020 Apr; 19(8):870-883. PubMed ID: 32178558 [TBL] [Abstract][Full Text] [Related]
16. miR-26a promotes hepatocellular carcinoma invasion and metastasis by inhibiting PTEN and inhibits cell growth by repressing EZH2. Zhao WT; Lin XL; Liu Y; Han LX; Li J; Lin TY; Shi JW; Wang SC; Lian M; Chen HW; Sun Y; Xu K; Jia JS; Luo RC; Xiao D Lab Invest; 2019 Oct; 99(10):1484-1500. PubMed ID: 31201367 [TBL] [Abstract][Full Text] [Related]
17. Epigenetic silencing of miR-144/451a cluster contributes to HCC progression via paracrine HGF/MIF-mediated TAM remodeling. Zhao J; Li H; Zhao S; Wang E; Zhu J; Feng D; Zhu Y; Dou W; Fan Q; Hu J; Jia L; Liu L Mol Cancer; 2021 Mar; 20(1):46. PubMed ID: 33658044 [TBL] [Abstract][Full Text] [Related]
18. MicroRNA-26a is a key regulon that inhibits progression and metastasis of c-Myc/EZH2 double high advanced hepatocellular carcinoma. Zhang X; Zhang X; Wang T; Wang L; Tan Z; Wei W; Yan B; Zhao J; Wu K; Yang A; Zhang R; Jia L Cancer Lett; 2018 Jul; 426():98-108. PubMed ID: 29653269 [TBL] [Abstract][Full Text] [Related]
19. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Lu J; He ML; Wang L; Chen Y; Liu X; Dong Q; Chen YC; Peng Y; Yao KT; Kung HF; Li XP Cancer Res; 2011 Jan; 71(1):225-33. PubMed ID: 21199804 [TBL] [Abstract][Full Text] [Related]
20. c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Wang L; Zhang X; Jia LT; Hu SJ; Zhao J; Yang JD; Wen WH; Wang Z; Wang T; Zhao J; Wang RA; Meng YL; Nie YZ; Dou KF; Chen SY; Yao LB; Fan DM; Zhang R; Yang AG Hepatology; 2014 May; 59(5):1850-63. PubMed ID: 24002871 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]